BACKGROUND: Although cystic fibrosis (CF) is the most common inherited respiratory disease, the burden of influenza among individuals with CF is not well characterized. METHODS: We used the CF Foundation Patient Registry to determine the relationship between pulmonary exacerbation incidence rate and influenza virus season from July 2003 through June 2007. The outcome of interest, pulmonary exacerbation, was defined as treatment of a respiratory illness with IV antibiotics. Each influenza season was defined as all months during which >/= 15% of laboratory tests for influenza virus were positive in the US influenza virologic surveillance system. We calculated incidence rates of pulmonary exacerbation during the influenza and summertime seasons as well as relative rates with 95% CIs. A multivariate regression model adjusted for demographic and clinical predictors. RESULTS: In 2003, the patient cohort size was 21,506 patients, and 7,727 patients experienced at least one pulmonary exacerbation. The overall pulmonary exacerbation incidence rate in the influenza season was 595.0 per 10,000 person-months compared with a summertime baseline of 549.6 per 10,000 person-months. The incidence rate ratio was 1.08 (95% CI: 1.06, 1.10). Multivariate analysis did not change our estimate of risk (adjusted odds ratio: 1.07; 95% CI: 1.05, 1.10). An estimated annual excess of 147.6 per 10,000 person-months or an excess 2.1% of total exacerbations occur during the influenza season. CONCLUSION: Our data demonstrate a substantial contribution of the influenza season to CF morbidity. Further studies to determine any causal link between influenza infection and CF pulmonary exacerbations are necessary.
BACKGROUND: Although cystic fibrosis (CF) is the most common inherited respiratory disease, the burden of influenza among individuals with CF is not well characterized. METHODS: We used the CF Foundation Patient Registry to determine the relationship between pulmonary exacerbation incidence rate and influenza virus season from July 2003 through June 2007. The outcome of interest, pulmonary exacerbation, was defined as treatment of a respiratory illness with IV antibiotics. Each influenza season was defined as all months during which >/= 15% of laboratory tests for influenza virus were positive in the US influenza virologic surveillance system. We calculated incidence rates of pulmonary exacerbation during the influenza and summertime seasons as well as relative rates with 95% CIs. A multivariate regression model adjusted for demographic and clinical predictors. RESULTS: In 2003, the patient cohort size was 21,506 patients, and 7,727 patients experienced at least one pulmonary exacerbation. The overall pulmonary exacerbation incidence rate in the influenza season was 595.0 per 10,000 person-months compared with a summertime baseline of 549.6 per 10,000 person-months. The incidence rate ratio was 1.08 (95% CI: 1.06, 1.10). Multivariate analysis did not change our estimate of risk (adjusted odds ratio: 1.07; 95% CI: 1.05, 1.10). An estimated annual excess of 147.6 per 10,000 person-months or an excess 2.1% of total exacerbations occur during the influenza season. CONCLUSION: Our data demonstrate a substantial contribution of the influenza season to CF morbidity. Further studies to determine any causal link between influenza infection and CF pulmonary exacerbations are necessary.
Authors: P Kramarz; F Destefano; P M Gargiullo; R T Chen; T A Lieu; R L Davis; J P Mullooly; S B Black; H R Shinefield; K Bohlke; J I Ward; S M Marcy Journal: J Pediatr Date: 2001-03 Impact factor: 4.406
Authors: Marie R Griffin; Christopher S Coffey; Kathleen M Neuzil; Edward F Mitchel; Peter F Wright; Kathryn M Edwards Journal: Arch Intern Med Date: 2002-06-10
Authors: Fatimah S Dawood; Seema Jain; Lyn Finelli; Michael W Shaw; Stephen Lindstrom; Rebecca J Garten; Larisa V Gubareva; Xiyan Xu; Carolyn B Bridges; Timothy M Uyeki Journal: N Engl J Med Date: 2009-05-07 Impact factor: 91.245
Authors: Gregory S Sawicki; Lawrence Rasouliyan; David J Pasta; Warren E Regelmann; Jeffrey S Wagener; David A Waltz; Clement L Ren Journal: Pediatr Pulmonol Date: 2008-11
Authors: William W Thompson; Eric Weintraub; Praveen Dhankhar; Po-Yung Cheng; Lynnette Brammer; Martin I Meltzer; Joseph S Bresee; David K Shay Journal: Influenza Other Respir Viruses Date: 2009-01 Impact factor: 4.380
Authors: Christopher H Goss; Stephanie J MacNeill; Hebe B Quinton; Bruce C Marshall; Alexander Elbert; Emily A Knapp; Kristofer Petren; Elaine Gunn; Joanne Osmond; Diana Bilton Journal: Thorax Date: 2014-09-25 Impact factor: 9.139
Authors: W G Flight; R J Bright-Thomas; C Sarran; K J Mutton; J Morris; A K Webb; A M Jones Journal: Int J Biometeorol Date: 2014-01-23 Impact factor: 3.787
Authors: Michelle N Eakin; Andrew Bilderback; Michael P Boyle; Peter J Mogayzel; Kristin A Riekert Journal: J Cyst Fibros Date: 2011-03-31 Impact factor: 5.482
Authors: Margaret Rosenfeld; Julia Emerson; Sharon McNamara; Valeria Thompson; Bonnie W Ramsey; Wayne Morgan; Ronald L Gibson Journal: J Cyst Fibros Date: 2012-05-01 Impact factor: 5.482
Authors: Ranjani Somayaji; Christopher H Goss; Umer Khan; Moni Neradilek; Kathleen M Neuzil; Justin R Ortiz Journal: Clin Infect Dis Date: 2017-06-15 Impact factor: 9.079
Authors: Jonathan Cogen; Julia Emerson; Don B Sanders; Clement Ren; Michael S Schechter; Ronald L Gibson; Wayne Morgan; Margaret Rosenfeld Journal: Pediatr Pulmonol Date: 2015-06-09